Division of Merck & Co. Inc.
Latest From MSD France
With its 2015 third fund Forbion Capital III yielding an internal rate of about 65% and already returning 60% of the money it drew down back to investors, it is probably no surprise that Forbion exceeded its €250M target for its predominantly Europe-focused Forbion IV fund within two months of marketing.
Eight EU marketing authorization applications are up for an opinion this week from the CHMP, the European Medicines Agency committee that recommends whether or not products should be approved.
Adnan Filipovic has 'a sense of mission' to get cancer sufferers in Bosnia and Herzegovina access to innovative drugs despite the huge obstacles in that war-damaged country.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Michel Vounatsos, Managing Dir.
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.